Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06720545
NA

Cardiometabolic Risk Effects of Short-term Cessation of Neurostimulation Therapy

Sponsor: Columbia University

View on ClinicalTrials.gov

Summary

Hypoglossal nerve stimulation (HGNS) is an implantable therapy that treats obstructive sleep apnea. The study will evaluate the effect of this treatment on cardiovascular and metabolism-related measures to see if it affects patients' risk of medical problems associated with obstructive sleep apnea (OSA).

Official title: Cardiometabolic Risk Effects of Short-term Cessation of Effective Neurostimulation Therapy in OSA

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2025-01-05

Completion Date

2028-01

Last Updated

2025-07-10

Healthy Volunteers

No

Interventions

DEVICE

No HGNS therapy (HGNS-off)

Prior to enrollment in this study, participants will have been utilizing HGNS at a therapeutic voltage setting confirmed via overnight sleep study. As part of the trial, they will undergo a study arm that involves turning off HGNS therapy (HGNS-off) for between 2-4 weeks.

Locations (1)

Columbia University Medical Center

New York, New York, United States